Cruiser Capital Advisors LLC reduced its position in shares of Enhabit, Inc. (NYSE:EHAB - Free Report) by 74.4% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 23,920 shares of the company's stock after selling 69,393 shares during the quarter. Cruiser Capital Advisors LLC's holdings in Enhabit were worth $187,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors and hedge funds have also bought and sold shares of the company. FMR LLC boosted its holdings in shares of Enhabit by 138.4% in the 3rd quarter. FMR LLC now owns 3,388 shares of the company's stock valued at $27,000 after buying an additional 1,967 shares in the last quarter. Quantbot Technologies LP acquired a new position in shares of Enhabit during the fourth quarter worth $45,000. Corient Private Wealth LLC acquired a new position in Enhabit during the 4th quarter valued at about $79,000. Intech Investment Management LLC acquired a new stake in Enhabit in the third quarter worth about $96,000. Finally, Stoneridge Investment Partners LLC grew its stake in shares of Enhabit by 22.6% during the fourth quarter. Stoneridge Investment Partners LLC now owns 12,533 shares of the company's stock worth $98,000 after acquiring an additional 2,308 shares during the last quarter.
Enhabit Stock Performance
EHAB traded down $0.29 during midday trading on Friday, hitting $8.64. 197,302 shares of the company were exchanged, compared to its average volume of 484,649. The firm has a market capitalization of $436.35 million, a price-to-earnings ratio of -3.73 and a beta of 1.80. The company's 50 day simple moving average is $8.52 and its 200 day simple moving average is $7.98. The company has a current ratio of 1.46, a quick ratio of 1.46 and a debt-to-equity ratio of 0.85. Enhabit, Inc. has a 1-year low of $6.85 and a 1-year high of $11.69.
Analyst Upgrades and Downgrades
Separately, Jefferies Financial Group reaffirmed a "buy" rating on shares of Enhabit in a research report on Thursday, March 6th.
View Our Latest Research Report on Enhabit
About Enhabit
(
Free Report)
Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.
Further Reading
Before you consider Enhabit, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enhabit wasn't on the list.
While Enhabit currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
